Pharmacy Benefit Manager Sunshine and Accountability Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Pharmacy Benefit Manager Sunshine and Accountability Act (H.R. 2816) is a legislative proposal introduced in the 118th Congress aimed at increasing transparency and accountability in the operations of pharmacy benefit managers (PBMs). PBMs are intermediaries that negotiate drug prices and manage prescription drug benefits for health plans. The bill seeks to address concerns about PBM practices by imposing disclosure requirements and oversight mechanisms. However, the official summary and full bill text are not available, limiting detailed analysis of specific provisions. The bill was referred to the House Subcommittee on Health but ultimately failed or expired without further action.
H.R. 2816 intended to enhance transparency and accountability of pharmacy benefit managers but did not advance beyond subcommittee referral and expired in the 118th Congress.
- The bill focuses on pharmacy benefit managers, entities that influence drug pricing and access.
- It aims to increase transparency and accountability in PBM operations through regulatory measures.
- The bill was referred to the House Subcommittee on Health on December 17, 2024, but did not progress further.
['Patients and consumers seeking clearer information on drug pricing and PBM practices', 'Health care providers and insurers affected by PBM policies', 'Regulatory bodies overseeing pharmaceutical and health care markets']
['Lack of available full text limits understanding of specific regulatory or enforcement mechanisms proposed', 'Potential administrative and compliance costs for PBMs and health plans', 'Unclear scope of oversight authority and enforcement provisions due to missing bill text']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It addresses ongoing policy discussions about the role of PBMs in drug pricing and health care costs. The bill did not advance beyond subcommittee referral and expired, indicating limited legislative momentum during this session.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Increased transparency requirements could lead to changes in PBM business practices affecting drug pricing negotiations.', 'Potential administrative burden on PBMs and health plans to comply with new disclosure rules.', 'Greater regulatory oversight may influence market dynamics in the pharmaceutical supply chain.']
The lack of a bill summary and full text limits transparency and public understanding of the Pharmacy Benefit Manager Sunshine and Accountability Act. This gap hinders effective oversight and informed stakeholder engagement. Future legislative proposals would benefit from comprehensive public documentation to facilitate analysis and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.